Current developments in pharmacological therapeutics for chronic constipation

被引:1
|
作者
Chunhuan Jiang [1 ]
Qinglong Xu [1 ]
Xiaoan Wen [1 ]
Hongbin Sun [1 ]
机构
[1] State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease,China Pharmaceutical University
基金
中国国家自然科学基金;
关键词
Chronic constipation; Prokinetic agent; 5-HT4; receptor; Prosecretory agent;
D O I
暂无
中图分类号
R574.62 [结肠疾病];
学科分类号
1002 ; 100201 ;
摘要
Chronic constipation is a common gastrointestinal disease severely affecting the patient’s quality of life. The traditional treatment of constipation is the use of laxatives. Recently, several new drugs including lubiprostone, linaclotide and prucalopride have been approved for treatment of chronic constipation. However, a significant unmet medical need still remains, particularly among those patients achieving poor results by current therapies. The 5-HT4 receptor modulators velusetrag and naronapride,the guanylate cyclase C agonist plecanatide and the ileal bile acid transporter inhibitor elobixibat are recognized as the most promising drugs under investigation. Herein, we give a comprehensive review on the pharmacological therapeutics for the treatment of chronic constipation, with the purpose of reflecting the drug development trends in this field.
引用
收藏
页码:300 / 309
页数:10
相关论文
共 50 条